Targeted therapies: Pazopanib: Carving a niche in a crowded therapeutic landscape

Nature Reviews Clinical Oncology

Volumn 7, Issue 7, 2010, Pages 362-363

  Pal, Sumanta Kumar ^a   Figlin, Robert A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; VASCULOTROPIN; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG USE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; LIVER TOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 77954240822     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.83     Document Type: Short Survey

References (10)

1. Us Food and Drug Administration. FDA approval letter for sorafenib [online], http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2005/ 021923ltr.pdf (2010).
2. Us Food and Drug Administration. FDA approval letter for sunitinib [online], http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2006/ 021968s000ltr.pdf (2010).
3. National Comprehensive Cancer network Clinical Practice Guidelines. Renal cell carcinoma [online]. http://www.nccn.org (2010).
4. Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. J. Clin. Oncol. 28, 1061-1068 (2010).
5. Sternberg, C. N. et al. A randomized, double-blind phase iii study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [abstract]. J. Clin. Oncol. 27 (suppl.), 5021 (2009).
6. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584-3590 (2009).
7. Escudier, B. J. et al. Final results of the phase III, randomized, double-blind AvORen trial of first-line bevacizumab (Bev) + interferon-α2a (iFn) in metastatic renal cell carcinoma (mRCC) [abstract]. J. Clin. Oncol. 27 (suppl.), 5020 (2009)
8. NCT00720941: study veG108844, a study of pazopanib versus sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma [online], http://www.clinicaltrials.gov/ct2/show/nCT00720941?term= veG108844&rank=1 (2010)
9. NCT01064310: A randomised double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment naïve locally advanced or metastatic renal cell carcinoma [online], http://www.clinicaltrials.gov/ct2/ show/nCT01064310?term=nCT01064310&rank=1 (2010).
10. Heymach, J. et al. Lower baseline levels of plasma hepatocyte growth factor (HGF), iL-6 and iL-8 are correlated with tumor shrinkage in renal cell carcinoma patients treated with pazopanib [abstract]. Mol Cancer. Ther. 8 (12 suppl.), a11 (2009).